

Research article

Open Access

le

## ***cagA* and *vacA* in strains of *Helicobacter pylori* from ulcer and non-ulcerative dyspepsia patients**

Gustavo Faundez, Miriam Troncoso and Guillermo Figueroa\*

Address: Laboratory of Microbiology, Institute of Nutrition and Food Technology. University of Chile. Macul 5540, Santiago, Chile

E-mail: Gustavo Faundez - gfaundez@uec.inta.uchile.cl; Miriam Troncoso - mtronco@uec.inta.uchile.cl;

Guillermo Figueroa\* - gfiguero@uec.inta.uchile.cl

\*Corresponding author

Published: 10 September 2002

Received: 14 March 2002

*BMC Gastroenterology* 2002, **2**:20

Accepted: 10 September 2002

This article is available from: <http://www.biomedcentral.com/1471-230X/2/20>

© 2002 Faundez et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.

### **Abstract**

**Background:** The cytotoxin associated gene A (*cagA*), and the vacuolating cytotoxin gene A (*vacA*) of *Helicobacter pylori* have been associated to phenotypic characteristics of virulence. The objectives of this study were to detect the presence of *cagA* and to characterize the allelic variants of *vacA* in 63 strains of *H. pylori* isolated from colonized individuals with different clinical outcomes.

**Methods:** 38 strains were isolated from patients with non-ulcerative dyspepsia (NUD) and 25 were isolated from colonized individuals with peptic ulcers. The genotypic characterization was carried out utilizing PCR methodology. The presence of the *cagA* gene was detected using two set of primers from the middle conservative region of the *cagA*, and primers for the signal and middle region were used for the genotyping of *vacA*

**Results:** The presence of *cagA* showed similar rates in strains from peptic ulcers (60%) and NUD patients (55%). Also similar was the prevalence of the allelic form sI of *vacA* between the strains obtained from ulcers or NUD patients. However, the combination *cagA*+/*vacA* sImI was found more frequently among the *H. pylori* strains from peptic ulcer patients (52%) than among strains isolated from NUD patients (26%), this difference was statistically significant ( $p = 0.035$ ).

**Conclusions:** The presence of either *cagA* or the allelic variant sI *vacA* alone do not have a predictive value as a risk markers of severe gastric pathologies in the Chilean population. However, being infected by a *H. pylori* strain with the genotype *cagA*+/*vacA* sImI may be associated to an increased risk of acquiring a peptic ulcer disease.

### **Background**

*Helicobacter pylori* infects about half of the world population, but only a reduced percentage develops peptic ulcers or gastric cancer, both conditions are strongly related with *H. pylori* infection in Chile [1]. It has been suggested that patients with severe gastroduodenal symptoms are infect-

ed with more virulent strains of *H. pylori*, while those individuals that just develop gastritis are infected with strains of low pathogenic potential. *cagA* is one of the markers for a pathogenicity island of ca. 40 kilobases, which has been associated to more severe clinical outcomes [2]. *vacA* codes for another important virulence fac-

tor that induces vacuolization on eukaryotic cells in vitro, and different allelic variants in two regions of this gene has been described. The N-terminal signal region (s) may occur as the alleles s1 (s1a and 1b) or s2 and the middle region (m) is present as alleles m1 or m2. The variable structure of this gene has been associated with differences in the production of the cytotoxin and the clinical outcome of the *H. pylori* infection [3].

In Chile, two gastroduodenal diseases, peptic ulcers and gastric cancer, are a frequent cause of medical consultation. Moreover, serological studies have indicated that an elevated percentage (over 70%) of asymptomatic adults over 35 years old, are infected by *H. pylori* [4].

The objective of this study was to evaluate the prevalence of the *cagA* gene and the allelic variants of the s and m regions of the *vacA* gene in *H. pylori* strains isolated from Chilean patients.

**Methods**

A total of 63 *H. pylori* strains were analyzed in this study. All strains were isolated from gastric biopsies, 25 from patients with gastroduodenal ulcers, and 38 from colonized individuals with non-ulcerative dyspepsia (NUD). *H. py-*

*lori* was identified by means of microscopic observation and urease, catalase and oxidase tests. Isolates were finally confirmed by PCR. The presence of the *cagA* gene was detected by PCR using two set of primers from the middle conservative region of the *cagA*: 5'-GATAACAGGCAAGCTTTTGAGAGGGA-3' and 5'-CCATGAATTTTTGATCCGTTCCG-3' originating a fragment of 393 bp [5] and 5'-GATAACAGGCAAGCTTTTGAGG-3' and 5'-CTGCAAAAGATTGTTTGGCAGA-3', which yield a fragment of 349 bp [6]. The genotyping of *vacA* was done by PCR. For the s region, the primers 5'-ATGGAAATACAACAAACACAC-3' and 5'-CTGCTTGAATGCGCCAAAC-3' originated fragments of 259 bp (s1 type) or fragments of 286 bp (s2 type) [3]. For the m region, the primers 5'-CAATCTGTCCAATCAAGCGAG-3' and 5'-GCGTCAAAATAATTCCAAGG-3' originated fragments of 567 bp (m1 type), or fragments of 642 bp (m2 type) [7]. The amplification products were evidenced through 2% agarose gel electrophoresis. Gels were stained with ethidium bromide, and observed under UV light. Comparative statistical analysis was done using the chi-square test.

**Table 1: Prevalence of *cagA* and allelic variants of *vacA* on the *H. pylori* strains isolated from patients with ulcer or NUD**

Gastroduodenal condition	CagA		VacA				
	CagA +	CagA -	S1	S2	m1	m2	m1m2
Ulcers*	15 (60%)	10 (40%)	16 (62%)	9 (38%)	13 (52%)	11 (44%)	1 (4%)
NUD**	21 (55%)	17 (45%)	20 (53%)	18 (47%)	14 (37%)	23 (60%)	1 (3%)

\*Strains isolated from ulcer patients (N = 25) \*\*Strains isolated from NUD patients (N = 38)

**Table 2: Prevalence of *cagA* related to the main allelic combinations of *vacA*.**

Gastroduodenal condition	cagA+			cagA-		
	s1m1	s1m2	s2m2	s1m1	s1m2	s2m2
Ulcers*	13 (52%)	0	2 (8%)	0	1 (4%)	8 (32%)
NUD**	10 (26%)	3 (8%)	7 (18%)	4 (11%)	2 (5%)	11 (29%)

\*Strains isolated from ulcer patients (N = 25) \*\*Strains isolated from NUD patients (N = 38)

## Results and Discussion

As shown in Table 1, the presence of *cagA* was similar in the groups studied, 15/25 (60%) in the strains from ulcer patients and 21/38 (55%) in the strains from NUD patients. The prevalence of the allelic variants of s1 and m1 of *vacA* was higher in the strains isolated from ulcer patients than in the strains from NUD patients (62% vs 53%, and 52% vs 37% respectively), however these differences were not statistically significant. The combinations s1m1 and s2m2 A were predominant, being s1m1 more prevalent in the strains obtained from ulcer patients (52% in ulcer and 40% in NUD), and s2m2 more prevalent in the strains from NUD cases (36% in ulcer and 47% in NUD), although these differences were not statistically significant. When the *cagA* and *vacA* genotypes were combined and analyzed in relation to the clinical outcome (Table 2), the *cagA*+ strains with the allelic variant s1m1 of *vacA* were more prevalent in the strains isolated from ulcers patients (52%) than in the strains from NUD patients (26%), this difference was statistically significant ( $p = 0.035$ ).

Several studies, have demonstrated that the genotype varies among *H. pylori* strains isolated from different geographic regions [8,9] and conclusions derived from one geographic region may not be true for others. Reports from developed countries have found that the *cagA* gene and the allelic variant s1 of *vacA* are more prevalent among strains of *H. pylori* isolated from patients with peptic ulcers [2,3,10]. In South America, De Gusmao *et al.* demonstrated an association between the presence of the s1 allele and the presence of duodenal ulcer, and also an association between the presence of the m1 allele of the *vacA* gene and the presence of peptic ulcers in Brazilian children [11]. On the other hand, reports from other geographical regions like Asian and some Latin American countries have found no association between the presence of *cagA* or the s1 allelic variant of *vacA* and the clinical outcome of an *H. pylori* infection [6,12–15]. Thus, Yamaoka *et al.* have concluded that no particular combination of *iceA*, *vacA*, and *cagA* is helpful in predicting a patient's disease status [6]. In our experience, taken individually, the presence of *cagA* or the allelic variant s1 of *vacA* do not have a predictive value as risk markers for the development severe gastric pathologies. However, the results presented here are somehow peculiar, since when we considered the prevalence of *cagA* and the allelic variants of *vacA* together, the *cagA*+/s1m1 combination was significantly more prevalent among the strains isolated from peptic ulcer patients than in NUD patients. Although the  $p$  value is near the borderline for the statistical significance, these data may reflect a tendency, which are supported by the use of two different sets of primers to evaluate the *cagA* status. These results then, suggest that in the Chilean population, being infected by a *H. pylori* strain

with the genotype *cagA*+/*vacA* s1m1 may be associated to an increased risk of acquiring an ulcer disease. The genetic predisposition of the population, and local environmental factors, may also be important factors in the development of diseases caused by *H. pylori*, which may explain the differences observed with respect to others Latin American countries. The geographical barriers existing in Chile might in part preserve these differences.

## Conclusions

The presence of *cagA* or the allelic variant s1 of *vacA* alone do not have a predictive value as risk markers for the development of ulcer disease among the Chilean population. However, being infected by a *H. pylori* strain with the genotype *cagA*+/*vacA* s1m1 may increase the risk of acquiring a peptic ulcer.

## Competing interests

None declared.

## Authors' contribution

GZF carried out the genotyping of the *H. pylori* strains by PCR, performed the statistical analysis, participated in the design of the study and drafted the manuscript. MT carried out the isolation of the *H. pylori* strains from patient's endoscopy samples. GF conceived the study and participated in its design.

## Acknowledgements

This work was supported by FONDECYT Grant 1990074

## References

1. Figueroa G, Acuña R, Troncoso M, Portell P, Toledo M, Valenzuela J: **Helicobacter pylori infection in Chile.** *Clin Infect Dis* 1997, **25**:983-9
2. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli M, Covacci A: **cagA, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors.** *Proc Natl Acad Sci* 1996, **93**:14648-14653
3. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ: **Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori.** *Gastroenterology* 1997, **112**:92-99
4. Medina E: **Las enfermedades digestivas en Chile: panorama epidemiológico.** *Rev Med Chile* 1988, **116**:282-8
5. Husson MO, Gottrand F, Vachee A, Dhaenens L, Martin de la Salle E, Turk D, Houcke M, Leclerc H: **Importance in diagnosis of gastritis of detection by PCR of the cagA Gene in Helicobacter pylori strains isolated from children,** *J Clin Microbiol* 1995, **33**:3300-3303
6. Yamahoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY: **Relationship between Helicobacter pylori iceA, cagA and vacA status and clinical outcome: studies in four different countries.** *J Clin Microbiol* 1999, **37**:2274-2279
7. Atherton JC, Cover T, Twells RJ, Morales MR, Hawkey CJ, Blaser MJ: **Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of H. pylori.** *J Clin Microbiol* 1999, **37**:2979-2982
8. Covacci A, Telford JL, Giudice GD, Parsonnet J, Rappuoli R: **Helicobacter pylori virulence and genetic geography.** *Science* 1999, **284**:1328-1333
9. Kersulyte D, Mukhopadhyay AK, Velapatino B, *et al*: **Differences in genotypes of Helicobacter pylori from different human populations.** *J Bacteriol* 2000, **182**:3210-3218

10. Rudi R, Kolb C, Maiwald D, Kuck D, Sieg A, Galle PR, Stremmel W: **Diversity of *Helicobacter pylori* vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases.** *J Clin Microbiol* 1998, **36**:944-948
11. De Gusmao VR, Mendes EN, De Magalhaes-Queiroz DM, Rocha GA, Rocha AMC, Ashour AAR, Carvalho AST: **vacA genotypes in *Helicobacter pylori* strains isolated from children with and without duodenal ulcer in Brazil.** *J Clin Microbiol* 2000, **38**:2853-2857
12. Chattopadhyay S, Datta S, Chowdhury A, et al: **Virulence genes in *Helicobacter pylori* strains from West Bengal residents with overt *H. pylori*-associated disease and healthy volunteers.** *J Clin Microbiol* 2002, **40**:2622
13. Tokumuru K, Kimura K, Saifuku K, Kojima T, Satoh K, Ido K: **CagA and cytotoxicity of *Helicobacter pylori* are not markers of peptic ulcer in Japanese patients.** *Helicobacter* 1999, **4**:1-6
14. Morales-Espinosa R, Castillo-Rojas G, Gonzalez-Valencia G, Ponce de León S, Cravioto A, Atherton JC, López-Vidal Y: **Colonization of Mexican patients by multiple *Helicobacter pylori* strains with different vacA and cagA genotypes** *J Clin Microbiol* 1999, **37**:3001-04
15. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omata M: **Major virulence factors, VacA and CagA, are commonly positive in *Helicobacter pylori* isolates in Japan.** *Gut* 1998, **42**:338-343

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-230X/2/20/pre-pub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)